ReJoin for KOA

Home / Stem Cells / ReJoin for KOA

ReJoin® Therapy for Knee Osteoarthritis

Phase IIb Trial Completed

Our ReJoin® human adipose-derived mesenchymal progenitor cell (haMPC) therapy for KOA is an interventional therapy that consists of adipose (fat) tissue obtained from the patient, and are then expanded using CBMG’s proprietary culture medium (serum-free and antibiotics-free), and formulated for ReJoin® therapy using CBMG’s proprietary formulation.

Name of StudyAutologous Adipose Tissue Derived Mesenchymal Progenitor Cells Therapy for Patients With Knee Osteoarthritis
PhaseClinical Trial IIb
StatusTrial Completed
48 Week Follow-Up Data - Cartilage regrowth as early as 3 months - VIEW HERE
ClinicalTrials.gov IdentifierNCT02162693 - view study online here
Study TypeInterventional
Study DesignAllocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Principal InvestigatorChunde Bao, MD
Hospital(s)Shanghai Renji Hospital

CBMG, in partnership with Renji Hospital affiliated with Shanghai Jiaotong University, completed a Phase I/IIa clinical trial in using haMPC’s to apply to KOA indications according to Chinese regulatory requirements.